Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 17/20 | 0.79 |
| ▸ | KLK1 | P06870 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10181912 | 0.89 | F10 (0.80) | F10NPC1TP53RAB9AKCNH2 | |
| SCHEMBL10177802 | 0.89 | F10 (0.77) | F10KLK1KMT2ATDP1KCNH2 | |
| SCHEMBL12132560 | 0.88 | F10 (1.00) | F10KCNH2 | |
| SCHEMBL15090378 | 0.88 | F10 (0.67) | F10KLK1KMT2ATDP1NPC1 | |
| SCHEMBL14404591 | 0.86 | F10 (0.76) | F10KCNH2 | |
| SCHEMBL10177762 | 0.83 | F10 (0.61) | F10KLK1KMT2ATDP1NPC1 | |
| SCHEMBL12132551 | 0.83 | F10 (0.63) | F10KLK1KMT2ATDP1NPC1 | |
| SCHEMBL890779 | 0.83 | F10 (0.76) | F10KLK1KMT2ATDP1NPC1 | |
| SCHEMBL13349191 | 0.82 | F10 (0.54) | F10KLK1KMT2ATDP1NPC1 | |
| SCHEMBL15090374 | 0.82 | F10 (0.71) | F10KLK1KMT2ATDP1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9108922-B2 | Benzamides and related inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-20140377247-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140377247-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | TFPI, F12, TFPI2 | F10 13/4885KLK1 637/4885KMT2A 1317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.